APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Nuclear Drug for Therapeutic

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Nuclear Drug for Therapeutic Market Analysis and Forecast 2026-2032

Report ID 17401805022 January 2026195 pages

Choose your research edition.

Industry ResearchNuclear Drug for Therapeutic Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Nuclear Drug for Therapeutic Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Nuclear Drug for Therapeutic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nuclear Drug for Therapeutic Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Nuclear Drug for Therapeutic Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Nuclear Drug for Therapeutic market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Nuclear Drug for Therapeutic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Nuclear Drug for Therapeutic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Nuclear Drug for Therapeutic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Nuclear Drug for Therapeutic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Nuclear Drug for Therapeutic include Aurobindo Pharma, China Isotope & Radiation, Curium Pharmaceuticals, Dongcheng, International Isotopes, Jubilant Radiopharma, Lantheus, Mundipharma and Q BioMed, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Nuclear Drug for Therapeutic, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Nuclear Drug for Therapeutic, also provides the revenue of main regions and countries. Of the upcoming market potential for Nuclear Drug for Therapeutic, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nuclear Drug for Therapeutic revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Nuclear Drug for Therapeutic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Nuclear Drug for Therapeutic revenue, projected growth trends, production technology, application and end-user industry.

Nuclear Drug for Therapeutic Segment by Company

Aurobindo Pharma

China Isotope & Radiation

Curium Pharmaceuticals

Dongcheng

International Isotopes

Jubilant Radiopharma

Lantheus

Mundipharma

Q BioMed

Bayer

Novartis

Nuclear Drug for Therapeutic Segment by Type

Iodine-131

Radium-223

Lutetium-177

Other

Nuclear Drug for Therapeutic Segment by Application

Lymphoma

Thyroid

Bone Metastasis

Other

Nuclear Drug for Therapeutic Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Drug for Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nuclear Drug for Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Drug for Therapeutic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Nuclear Drug for Therapeutic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Nuclear Drug for Therapeutic company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nuclear Drug for Therapeutic revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Nuclear Drug for Therapeutic Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Iodine-131 Major Player Table 3. Radium-223 Major Player Table 4. Lutetium-177 Major Player Table 5. Other Major Player Table 6. Global Nuclear Drug for Therapeutic Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Lymphoma Major Player Table 8. Thyroid Major Player Table 9. Bone Metastasis Major Player Table 10. Other Major Player Table 11. Nuclear Drug for Therapeutic Industry Trends Table 12. Nuclear Drug for Therapeutic Industry Drivers Table 13. Nuclear Drug for Therapeutic Industry Opportunities and Challenges Table 14. Nuclear Drug for Therapeutic Industry Restraints Table 15. Global Nuclear Drug for Therapeutic Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Nuclear Drug for Therapeutic Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Nuclear Drug for Therapeutic Market Share by Region (2021-2026) Table 18. Global Nuclear Drug for Therapeutic Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Nuclear Drug for Therapeutic Market Share by Region (2027-2032) Table 20. Global Nuclear Drug for Therapeutic Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Nuclear Drug for Therapeutic Revenue Market Share by Players (2021-2026) Table 22. Global Nuclear Drug for Therapeutic Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Nuclear Drug for Therapeutic Key Players Headquarters & Area Served Table 24. Global Nuclear Drug for Therapeutic Players, Product Type & Application Table 25. Global Nuclear Drug for Therapeutic Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Nuclear Drug for Therapeutic by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Nuclear Drug for Therapeutic Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Nuclear Drug for Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Nuclear Drug for Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Nuclear Drug for Therapeutic Revenue Market Share by Type (2021-2026) Table 32. Global Nuclear Drug for Therapeutic Revenue Market Share by Type (2027-2032) Table 33. Global Nuclear Drug for Therapeutic Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Nuclear Drug for Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Nuclear Drug for Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Nuclear Drug for Therapeutic Revenue Market Share by Application (2021-2026) Table 37. Global Nuclear Drug for Therapeutic Revenue Market Share by Application (2027-2032) Table 38. Aurobindo Pharma Company Information Table 39. Aurobindo Pharma Business Overview Table 40. Aurobindo Pharma Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Aurobindo Pharma Nuclear Drug for Therapeutic Product Portfolio Table 42. Aurobindo Pharma Recent Development Table 43. China Isotope & Radiation Company Information Table 44. China Isotope & Radiation Business Overview Table 45. China Isotope & Radiation Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. China Isotope & Radiation Nuclear Drug for Therapeutic Product Portfolio Table 47. China Isotope & Radiation Recent Development Table 48. Curium Pharmaceuticals Company Information Table 49. Curium Pharmaceuticals Business Overview Table 50. Curium Pharmaceuticals Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Curium Pharmaceuticals Nuclear Drug for Therapeutic Product Portfolio Table 52. Curium Pharmaceuticals Recent Development Table 53. Dongcheng Company Information Table 54. Dongcheng Business Overview Table 55. Dongcheng Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Dongcheng Nuclear Drug for Therapeutic Product Portfolio Table 57. Dongcheng Recent Development Table 58. International Isotopes Company Information Table 59. International Isotopes Business Overview Table 60. International Isotopes Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. International Isotopes Nuclear Drug for Therapeutic Product Portfolio Table 62. International Isotopes Recent Development Table 63. Jubilant Radiopharma Company Information Table 64. Jubilant Radiopharma Business Overview Table 65. Jubilant Radiopharma Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Jubilant Radiopharma Nuclear Drug for Therapeutic Product Portfolio Table 67. Jubilant Radiopharma Recent Development Table 68. Lantheus Company Information Table 69. Lantheus Business Overview Table 70. Lantheus Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Lantheus Nuclear Drug for Therapeutic Product Portfolio Table 72. Lantheus Recent Development Table 73. Mundipharma Company Information Table 74. Mundipharma Business Overview Table 75. Mundipharma Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Mundipharma Nuclear Drug for Therapeutic Product Portfolio Table 77. Mundipharma Recent Development Table 78. Q BioMed Company Information Table 79. Q BioMed Business Overview Table 80. Q BioMed Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Q BioMed Nuclear Drug for Therapeutic Product Portfolio Table 82. Q BioMed Recent Development Table 83. Bayer Company Information Table 84. Bayer Business Overview Table 85. Bayer Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Bayer Nuclear Drug for Therapeutic Product Portfolio Table 87. Bayer Recent Development Table 88. Novartis Company Information Table 89. Novartis Business Overview Table 90. Novartis Nuclear Drug for Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Novartis Nuclear Drug for Therapeutic Product Portfolio Table 92. Novartis Recent Development Table 93. North America Nuclear Drug for Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 94. North America Nuclear Drug for Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 95. North America Nuclear Drug for Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 96. North America Nuclear Drug for Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 97. North America Nuclear Drug for Therapeutic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. North America Nuclear Drug for Therapeutic Revenue by Country (2021-2026) & (US$ Million) Table 99. North America Nuclear Drug for Therapeutic Revenue by Country (US$ Million) & (2027-2032) Table 100. Europe Nuclear Drug for Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 101. Europe Nuclear Drug for Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 102. Europe Nuclear Drug for Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 103. Europe Nuclear Drug for Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 104. Europe Nuclear Drug for Therapeutic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 105. Europe Nuclear Drug for Therapeutic Revenue by Country (2021-2026) & (US$ Million) Table 106. Europe Nuclear Drug for Therapeutic Revenue by Country (US$ Million) & (2027-2032) Table 107. China Nuclear Drug for Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 108. China Nuclear Drug for Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 109. China Nuclear Drug for Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 110. China Nuclear Drug for Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 111. Asia Nuclear Drug for Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 112. Asia Nuclear Drug for Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 113. Asia Nuclear Drug for Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 114. Asia Nuclear Drug for Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 115. Asia Nuclear Drug for Therapeutic Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 116. Asia Nuclear Drug for Therapeutic Revenue by Region (US$ Million) & (2021-2026) Table 117. Asia Nuclear Drug for Therapeutic Revenue by Region (US$ Million) & (2027-2032) Table 118. SAMEA Nuclear Drug for Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 119. SAMEA Nuclear Drug for Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 120. SAMEA Nuclear Drug for Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 121. SAMEA Nuclear Drug for Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 122. SAMEA Nuclear Drug for Therapeutic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 123. SAMEA Nuclear Drug for Therapeutic Revenue by Country (2021-2026) & (US$ Million) Table 124. SAMEA Nuclear Drug for Therapeutic Revenue by Country (US$ Million) & (2027-2032) Table 125. Research Programs/Design for This Report Table 126. Authors List of This Report Table 127. Secondary Sources Table 128. Primary Sources List of Figures Figure 1. Nuclear Drug for Therapeutic Image Figure 2. Global Nuclear Drug for Therapeutic Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nuclear Drug for Therapeutic Market Size Share 2021 VS 2025 VS 2032 Figure 4. Iodine-131 Image Figure 5. Radium-223 Image Figure 6. Lutetium-177 Image Figure 7. Other Image Figure 8. Global Nuclear Drug for Therapeutic Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Nuclear Drug for Therapeutic Market Size Share 2021 VS 2025 VS 2032 Figure 10. Lymphoma Image Figure 11. Thyroid Image Figure 12. Bone Metastasis Image Figure 13. Other Image Figure 14. Global Nuclear Drug for Therapeutic Market Size (US$ Million) & (2021-2032) Figure 15. Global Nuclear Drug for Therapeutic Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Nuclear Drug for Therapeutic Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Nuclear Drug for Therapeutic Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Nuclear Drug for Therapeutic Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Nuclear Drug for Therapeutic Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Nuclear Drug for Therapeutic Revenue Market Share by Type (2021-2032) Figure 22. Global Nuclear Drug for Therapeutic Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Nuclear Drug for Therapeutic Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Nuclear Drug for Therapeutic Revenue Market Share by Application (2021-2032) Figure 25. North America Nuclear Drug for Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Nuclear Drug for Therapeutic Revenue Share by Type (2021-2032) Figure 27. North America Nuclear Drug for Therapeutic Revenue Share by Application (2021-2032) Figure 28. North America Nuclear Drug for Therapeutic Revenue Share by Country (2021-2032) Figure 29. United States Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Nuclear Drug for Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Nuclear Drug for Therapeutic Revenue Share by Type (2021-2032) Figure 34. Europe Nuclear Drug for Therapeutic Revenue Share by Application (2021-2032) Figure 35. Europe Nuclear Drug for Therapeutic Revenue Share by Country (2021-2032) Figure 36. Germany Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Nuclear Drug for Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Nuclear Drug for Therapeutic Revenue Share by Type (2021-2032) Figure 46. China Nuclear Drug for Therapeutic Revenue Share by Application (2021-2032) Figure 47. Asia Nuclear Drug for Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Nuclear Drug for Therapeutic Revenue Share by Type (2021-2032) Figure 49. Asia Nuclear Drug for Therapeutic Revenue Share by Application (2021-2032) Figure 50. Asia Nuclear Drug for Therapeutic Revenue Share by Region (2021-2032) Figure 51. Japan Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Nuclear Drug for Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Nuclear Drug for Therapeutic Revenue Share by Type (2021-2032) Figure 59. SAMEA Nuclear Drug for Therapeutic Revenue Share by Application (2021-2032) Figure 60. SAMEA Nuclear Drug for Therapeutic Revenue Share by Country (2021-2032) Figure 61. Brazil Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Nuclear Drug for Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Iodine-131
  • Radium-223
  • Lutetium-177
  • Other
Applications
  • Lymphoma
  • Thyroid
  • Bone Metastasis
  • Other
Companies covered
  • Aurobindo Pharma
  • China Isotope & Radiation
  • Curium Pharmaceuticals
  • Dongcheng
  • International Isotopes
  • Jubilant Radiopharma
  • Lantheus
  • Mundipharma
  • Q BioMed
  • Bayer
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Nuclear Drug for Therapeutic Market by Type
  3. 1.2.1 Global Nuclear Drug for Therapeutic Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Iodine-131
  5. 1.2.3 Radium-223
  6. 1.2.4 Lutetium-177
  7. 1.2.5 Other
  8. 1.3 Nuclear Drug for Therapeutic Market by Application
  9. 1.3.1 Global Nuclear Drug for Therapeutic Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Lymphoma
  11. 1.3.3 Thyroid
  12. 1.3.4 Bone Metastasis
  13. 1.3.5 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Nuclear Drug for Therapeutic Market Dynamics
  1. 2.1 Nuclear Drug for Therapeutic Industry Trends
  2. 2.2 Nuclear Drug for Therapeutic Industry Drivers
  3. 2.3 Nuclear Drug for Therapeutic Industry Opportunities and Challenges
  4. 2.4 Nuclear Drug for Therapeutic Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Nuclear Drug for Therapeutic Market Perspective (2021-2032)
  2. 3.2 Global Nuclear Drug for Therapeutic Growth Trends by Region
  3. 3.2.1 Global Nuclear Drug for Therapeutic Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Nuclear Drug for Therapeutic Market Size by Region (2021-2026)
  5. 3.2.3 Global Nuclear Drug for Therapeutic Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Nuclear Drug for Therapeutic Revenue by Players
  2. 4.1.1 Global Nuclear Drug for Therapeutic Revenue by Players (2021-2026)
  3. 4.1.2 Global Nuclear Drug for Therapeutic Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Nuclear Drug for Therapeutic Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Nuclear Drug for Therapeutic Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Nuclear Drug for Therapeutic Key Players Headquarters & Area Served
  7. 4.4 Global Nuclear Drug for Therapeutic Players, Product Type & Application
  8. 4.5 Global Nuclear Drug for Therapeutic Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Nuclear Drug for Therapeutic Market CR5 and HHI
  11. 4.6.3 2025 Nuclear Drug for Therapeutic Tier 1, Tier 2, and Tier 3
5 Nuclear Drug for Therapeutic Market Size by Type
  1. 5.1 Global Nuclear Drug for Therapeutic Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Nuclear Drug for Therapeutic Revenue by Type (2021-2032)
  3. 5.3 Global Nuclear Drug for Therapeutic Revenue Market Share by Type (2021-2032)
6 Nuclear Drug for Therapeutic Market Size by Application
  1. 6.1 Global Nuclear Drug for Therapeutic Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Nuclear Drug for Therapeutic Revenue by Application (2021-2032)
  3. 6.3 Global Nuclear Drug for Therapeutic Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Aurobindo Pharma
  2. 7.1.1 Aurobindo Pharma Company Information
  3. 7.1.2 Aurobindo Pharma Business Overview
  4. 7.1.3 Aurobindo Pharma Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Aurobindo Pharma Nuclear Drug for Therapeutic Product Portfolio
  6. 7.1.5 Aurobindo Pharma Recent Developments
  7. 7.2 China Isotope & Radiation
  8. 7.2.1 China Isotope & Radiation Company Information
  9. 7.2.2 China Isotope & Radiation Business Overview
  10. 7.2.3 China Isotope & Radiation Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  11. 7.2.4 China Isotope & Radiation Nuclear Drug for Therapeutic Product Portfolio
  12. 7.2.5 China Isotope & Radiation Recent Developments
  13. 7.3 Curium Pharmaceuticals
  14. 7.3.1 Curium Pharmaceuticals Company Information
  15. 7.3.2 Curium Pharmaceuticals Business Overview
  16. 7.3.3 Curium Pharmaceuticals Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Curium Pharmaceuticals Nuclear Drug for Therapeutic Product Portfolio
  18. 7.3.5 Curium Pharmaceuticals Recent Developments
  19. 7.4 Dongcheng
  20. 7.4.1 Dongcheng Company Information
  21. 7.4.2 Dongcheng Business Overview
  22. 7.4.3 Dongcheng Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Dongcheng Nuclear Drug for Therapeutic Product Portfolio
  24. 7.4.5 Dongcheng Recent Developments
  25. 7.5 International Isotopes
  26. 7.5.1 International Isotopes Company Information
  27. 7.5.2 International Isotopes Business Overview
  28. 7.5.3 International Isotopes Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  29. 7.5.4 International Isotopes Nuclear Drug for Therapeutic Product Portfolio
  30. 7.5.5 International Isotopes Recent Developments
  31. 7.6 Jubilant Radiopharma
  32. 7.6.1 Jubilant Radiopharma Company Information
  33. 7.6.2 Jubilant Radiopharma Business Overview
  34. 7.6.3 Jubilant Radiopharma Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Jubilant Radiopharma Nuclear Drug for Therapeutic Product Portfolio
  36. 7.6.5 Jubilant Radiopharma Recent Developments
  37. 7.7 Lantheus
  38. 7.7.1 Lantheus Company Information
  39. 7.7.2 Lantheus Business Overview
  40. 7.7.3 Lantheus Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Lantheus Nuclear Drug for Therapeutic Product Portfolio
  42. 7.7.5 Lantheus Recent Developments
  43. 7.8 Mundipharma
  44. 7.8.1 Mundipharma Company Information
  45. 7.8.2 Mundipharma Business Overview
  46. 7.8.3 Mundipharma Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Mundipharma Nuclear Drug for Therapeutic Product Portfolio
  48. 7.8.5 Mundipharma Recent Developments
  49. 7.9 Q BioMed
  50. 7.9.1 Q BioMed Company Information
  51. 7.9.2 Q BioMed Business Overview
  52. 7.9.3 Q BioMed Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Q BioMed Nuclear Drug for Therapeutic Product Portfolio
  54. 7.9.5 Q BioMed Recent Developments
  55. 7.10 Bayer
  56. 7.10.1 Bayer Company Information
  57. 7.10.2 Bayer Business Overview
  58. 7.10.3 Bayer Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Bayer Nuclear Drug for Therapeutic Product Portfolio
  60. 7.10.5 Bayer Recent Developments
  61. 7.11 Novartis
  62. 7.11.1 Novartis Company Information
  63. 7.11.2 Novartis Business Overview
  64. 7.11.3 Novartis Nuclear Drug for Therapeutic Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Novartis Nuclear Drug for Therapeutic Product Portfolio
  66. 7.11.5 Novartis Recent Developments
8 North America
  1. 8.1 North America Nuclear Drug for Therapeutic Revenue (2021-2032)
  2. 8.2 North America Nuclear Drug for Therapeutic Revenue by Type (2021-2032)
  3. 8.2.1 North America Nuclear Drug for Therapeutic Revenue by Type (2021-2026)
  4. 8.2.2 North America Nuclear Drug for Therapeutic Revenue by Type (2027-2032)
  5. 8.3 North America Nuclear Drug for Therapeutic Revenue Share by Type (2021-2032)
  6. 8.4 North America Nuclear Drug for Therapeutic Revenue by Application (2021-2032)
  7. 8.4.1 North America Nuclear Drug for Therapeutic Revenue by Application (2021-2026)
  8. 8.4.2 North America Nuclear Drug for Therapeutic Revenue by Application (2027-2032)
  9. 8.5 North America Nuclear Drug for Therapeutic Revenue Share by Application (2021-2032)
  10. 8.6 North America Nuclear Drug for Therapeutic Revenue by Country
  11. 8.6.1 North America Nuclear Drug for Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Nuclear Drug for Therapeutic Revenue by Country (2021-2026)
  13. 8.6.3 North America Nuclear Drug for Therapeutic Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Nuclear Drug for Therapeutic Revenue (2021-2032)
  2. 9.2 Europe Nuclear Drug for Therapeutic Revenue by Type (2021-2032)
  3. 9.2.1 Europe Nuclear Drug for Therapeutic Revenue by Type (2021-2026)
  4. 9.2.2 Europe Nuclear Drug for Therapeutic Revenue by Type (2027-2032)
  5. 9.3 Europe Nuclear Drug for Therapeutic Revenue Share by Type (2021-2032)
  6. 9.4 Europe Nuclear Drug for Therapeutic Revenue by Application (2021-2032)
  7. 9.4.1 Europe Nuclear Drug for Therapeutic Revenue by Application (2021-2026)
  8. 9.4.2 Europe Nuclear Drug for Therapeutic Revenue by Application (2027-2032)
  9. 9.5 Europe Nuclear Drug for Therapeutic Revenue Share by Application (2021-2032)
  10. 9.6 Europe Nuclear Drug for Therapeutic Revenue by Country
  11. 9.6.1 Europe Nuclear Drug for Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Nuclear Drug for Therapeutic Revenue by Country (2021-2026)
  13. 9.6.3 Europe Nuclear Drug for Therapeutic Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Nuclear Drug for Therapeutic Revenue (2021-2032)
  2. 10.2 China Nuclear Drug for Therapeutic Revenue by Type (2021-2032)
  3. 10.2.1 China Nuclear Drug for Therapeutic Revenue by Type (2021-2026)
  4. 10.2.2 China Nuclear Drug for Therapeutic Revenue by Type (2027-2032)
  5. 10.3 China Nuclear Drug for Therapeutic Revenue Share by Type (2021-2032)
  6. 10.4 China Nuclear Drug for Therapeutic Revenue by Application (2021-2032)
  7. 10.4.1 China Nuclear Drug for Therapeutic Revenue by Application (2021-2026)
  8. 10.4.2 China Nuclear Drug for Therapeutic Revenue by Application (2027-2032)
  9. 10.5 China Nuclear Drug for Therapeutic Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Nuclear Drug for Therapeutic Revenue (2021-2032)
  2. 11.2 Asia Nuclear Drug for Therapeutic Revenue by Type (2021-2032)
  3. 11.2.1 Asia Nuclear Drug for Therapeutic Revenue by Type (2021-2026)
  4. 11.2.2 Asia Nuclear Drug for Therapeutic Revenue by Type (2027-2032)
  5. 11.3 Asia Nuclear Drug for Therapeutic Revenue Share by Type (2021-2032)
  6. 11.4 Asia Nuclear Drug for Therapeutic Revenue by Application (2021-2032)
  7. 11.4.1 Asia Nuclear Drug for Therapeutic Revenue by Application (2021-2026)
  8. 11.4.2 Asia Nuclear Drug for Therapeutic Revenue by Application (2027-2032)
  9. 11.5 Asia Nuclear Drug for Therapeutic Revenue Share by Application (2021-2032)
  10. 11.6 Asia Nuclear Drug for Therapeutic Revenue by Country
  11. 11.6.1 Asia Nuclear Drug for Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Nuclear Drug for Therapeutic Revenue by Country (2021-2026)
  13. 11.6.3 Asia Nuclear Drug for Therapeutic Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Nuclear Drug for Therapeutic Revenue (2021-2032)
  2. 12.2 SAMEA Nuclear Drug for Therapeutic Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Nuclear Drug for Therapeutic Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Nuclear Drug for Therapeutic Revenue by Type (2027-2032)
  5. 12.3 SAMEA Nuclear Drug for Therapeutic Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Nuclear Drug for Therapeutic Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Nuclear Drug for Therapeutic Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Nuclear Drug for Therapeutic Revenue by Application (2027-2032)
  9. 12.5 SAMEA Nuclear Drug for Therapeutic Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Nuclear Drug for Therapeutic Revenue by Country
  11. 12.6.1 SAMEA Nuclear Drug for Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Nuclear Drug for Therapeutic Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Nuclear Drug for Therapeutic Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst